Advancing the technology of septal occlusion
Carag is proud to have led the development of the atHeart Medical reSept™ ASD Occluder, the first and only occluder with a metal-free, low-profile, bioresorbable frame intended for percutaneous occlusion of atrial septal defects (ASD). The company’s engineering and design expertise has brought this innovation from concept to successful clinical use.
At Carag, I encountered quality medtech engineering and a rare ability to turn ideas from the drawing board into working medical devices, thanks to an impressive concentration of competence, passion and dedication to problem solving.
Laurent Grandidier, Managing Director, atHeart Medical AG